IM Cannabis Regains Compliance with Nasdaq Minimum Bid Price Requirement
Nasdaq’s determination followed 18 consecutive business days with closing bids of at least $1.00 per share.
Rhea-AI Summary
IM Cannabis (IMCC) regained compliance with Nasdaq’s $1.00 minimum bid price rule on September 23, 2026, closing its bid price deficiency matter.
Nasdaq issued written notice after the closing bid price of the company’s ordinary shares was at least $1.00 per share for 18 consecutive business days, from August 27 through September 22, 2026. The company currently operates in Israel and Germany. If pending transactions announced on August 17, 2026, are completed, IM Cannabis expects to retain its Israeli medical cannabis operations and sell its German operations.
Positive
- Nasdaq bid price deficiency closed September 23, 2026
Negative
- None.
Details
Market move: IMCC +21.03% vs previous close. Nasdaq compliance restoration
On Sep 23, the day this news came out, the latest delayed price for IMCC is 21.03% above the previous close. Argus tracked a trough of -1.9% from its starting point during tracking. Our momentum scanner has recorded 136 alerts for this stock so far that day. The latest delayed price is $3.52. Relative volume is exceptionally heavy at 377.7x the average.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Minimum bid price requirement
- $1.00 per share
- Nasdaq Listing Rule 5550(a)(2)
- Consecutive closing bid-price days
- 18 business days
- August 27 to September 22, 2026; closing bid price was at least $1.00 per share
Historical Context
-
30:1 consolidation began trading to support Nasdaq minimum bid-price compliance.
-
Board approved 30-for-1 consolidation to address Nasdaq minimum bid-price requirement.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
The Nasdaq staff made this determination of compliance after the closing bid price of the Company's ordinary shares was
About IM Cannabis Corp.
IMCC (Nasdaq: IMCC) is an international company currently operating a medical cannabis platform serving patients in Israel and, through Adjupharm GmbH, Germany. Following completion of the pending transactions announced by the Company on August 17, 2026, the Company expects to retain its Israeli medical cannabis operations and the German operations will be sold.
The IMCC ecosystem operates in Israel through its subsidiaries, which import and distribute cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies and online platforms in Israel that enable the safe delivery and quality control of IMCC's products throughout the value chain.
Company Contact:
Michal Efraty
Investor & Public Relations
IM Cannabis Corp.
michal@efraty.com
Oren Shuster, Chief Executive Officer
IM Cannabis Corp.
info@imcannabis.com
Logo - https://mma.prnewswire.com/media/1742228/IM_Cannabis_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/im-cannabis-regains-compliance-with-nasdaq-minimum-bid-price-requirement-302888181.html
SOURCE IM Cannabis Corp.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How did IM Cannabis (IMCC) regain compliance with Nasdaq’s minimum bid price rule?
Nasdaq determined that IM Cannabis had regained compliance after its ordinary shares closed at $1.00 per share or greater for 18 consecutive business days, from August 27 through September 22, 2026. Nasdaq issued written notice on September 23, 2026, and considers the bid price deficiency matter closed.